240 related articles for article (PubMed ID: 25967538)
1. Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems.
Chen R; Wang H; Shi J; Shen K; Hu P
Eur J Clin Pharmacol; 2015 Jul; 71(7):835-41. PubMed ID: 25967538
[TBL] [Abstract][Full Text] [Related]
2. Polymorphism in CYP2D6 affects the pharmacokinetics and dose escalation of paroxetine controlled-release tablet in healthy Chinese subjects.
Chen R; Shen K; Hu P
Int J Clin Pharmacol Ther; 2017 Nov; 55(11):853-860. PubMed ID: 28933337
[TBL] [Abstract][Full Text] [Related]
3. Relationship of paroxetine disposition to metoprolol metabolic ratio and CYP2D6*10 genotype of Korean subjects.
Yoon YR; Cha IJ; Shon JH; Kim KA; Cha YN; Jang IJ; Park CW; Shin SG; Flockhart DA; Shin JG
Clin Pharmacol Ther; 2000 May; 67(5):567-76. PubMed ID: 10824636
[TBL] [Abstract][Full Text] [Related]
4. Single- and multiple-dose pharmacokinetics and tolerability of a paroxetine controlled-release tablet in healthy Chinese subjects
.
Chen R; Shen K; Hu P
Int J Clin Pharmacol Ther; 2017 Mar; 55(3):231-236. PubMed ID: 27936523
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study.
Nichols AI; Focht K; Jiang Q; Preskorn SH; Kane CP
Clin Drug Investig; 2011; 31(3):155-67. PubMed ID: 21288052
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and bioavailability comparison of generic and branded citalopram 20 mg tablets: an open-label, randomized-sequence, two-period crossover study in healthy Chinese CYP2C19 extensive metabolizers.
Jiang T; Rong Z; Xu Y; Chen B; Xie Y; Chen C; Lu Y; Shen Y; Li H; Sun J; Chen H
Clin Drug Investig; 2013 Jan; 33(1):1-9. PubMed ID: 23179471
[TBL] [Abstract][Full Text] [Related]
7. The relationship between clinical pharmacokinetics of aripiprazole and CYP2D6 genetic polymorphism: effects of CYP enzyme inhibition by coadministration of paroxetine or fluvoxamine.
Azuma J; Hasunuma T; Kubo M; Miyatake M; Koue T; Higashi K; Fujiwara T; Kitahara S; Katano T; Hara S
Eur J Clin Pharmacol; 2012 Jan; 68(1):29-37. PubMed ID: 21739267
[TBL] [Abstract][Full Text] [Related]
8. Influence of the cytochrome P450 2D6 *10/*10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis.
Nishimura M; Ueda M; Saruwatari J; Nakashima H; Ogusu N; Aoki A; Tsuchimine S; Matsuda K; Iwashita K; Ono T; Oniki K; Shimoda K; Yasui-Furukori N
Pharmacogenet Genomics; 2016 Sep; 26(9):403-13. PubMed ID: 27187662
[TBL] [Abstract][Full Text] [Related]
9. Reboxetine and cytochrome P450--comparison with paroxetine treatment in humans.
Kuhn UD; Kirsch M; Merkel U; Eberhardt AM; Wenda B; Maurer I; Härtter S; Hiemke C; Volz HP; Balogh A
Int J Clin Pharmacol Ther; 2007 Jan; 45(1):36-46. PubMed ID: 17256449
[TBL] [Abstract][Full Text] [Related]
10. Contribution of cytochrome P450 2D6 to 3,4-methylenedioxymethamphetamine disposition in humans: use of paroxetine as a metabolic inhibitor probe.
Segura M; Farré M; Pichini S; Peiró AM; Roset PN; Ramírez A; Ortuño J; Pacifici R; Zuccaro P; Segura J; de la Torre R
Clin Pharmacokinet; 2005; 44(6):649-60. PubMed ID: 15910012
[TBL] [Abstract][Full Text] [Related]
11. Terbinafine increases the plasma concentration of paroxetine after a single oral administration of paroxetine in healthy subjects.
Yasui-Furukori N; Saito M; Inoue Y; Niioka T; Sato Y; Tsuchimine S; Kaneko S
Eur J Clin Pharmacol; 2007 Jan; 63(1):51-6. PubMed ID: 17124578
[TBL] [Abstract][Full Text] [Related]
12. Cytochrome P450 2D6*10 genotype affects the pharmacokinetics of dimemorfan in healthy Chinese subjects.
Pei Q; Peng J; Tan H; Yang L; Yang X; Liu L; Liu S; Yuan H; Yang G
Eur J Drug Metab Pharmacokinet; 2015 Dec; 40(4):427-33. PubMed ID: 25159483
[TBL] [Abstract][Full Text] [Related]
13. Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling.
Feng Y; Pollock BG; Ferrell RE; Kimak MA; Reynolds CF; Bies RR
Br J Clin Pharmacol; 2006 May; 61(5):558-69. PubMed ID: 16669849
[TBL] [Abstract][Full Text] [Related]
14. Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes.
Jung EH; Lee YJ; Kim DH; Kang P; Lim CW; Cho CK; Jang CG; Lee SY; Bae JW
Arch Pharm Res; 2020 Dec; 43(12):1356-1363. PubMed ID: 33245517
[TBL] [Abstract][Full Text] [Related]
15. Effects of dosage and CYP2D6-mutated allele on plasma concentration of paroxetine.
Sawamura K; Suzuki Y; Someya T
Eur J Clin Pharmacol; 2004 Oct; 60(8):553-7. PubMed ID: 15349705
[TBL] [Abstract][Full Text] [Related]
16. Precision dosing-based optimisation of paroxetine during pregnancy for poor and ultrarapid CYP2D6 metabolisers: a virtual clinical trial pharmacokinetics study.
Almurjan A; Macfarlane H; Badhan RKS
J Pharm Pharmacol; 2020 Aug; 72(8):1049-1060. PubMed ID: 32346890
[TBL] [Abstract][Full Text] [Related]
17. Sex differences in 3,4-methylenedioxymethamphetamine (MDMA; ecstasy)-induced cytochrome P450 2D6 inhibition in humans.
Yubero-Lahoz S; Pardo R; Farré M; O'Mahony B; Torrens M; Mustata C; Pérez-Mañá C; Carbó ML; de la Torre R
Clin Pharmacokinet; 2011 May; 50(5):319-29. PubMed ID: 21456632
[TBL] [Abstract][Full Text] [Related]
18. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
[TBL] [Abstract][Full Text] [Related]
19. Cytochrome P450 2D6 genotype does not predict SSRI (fluoxetine or paroxetine) induced hyponatraemia.
Stedman CA; Begg EJ; Kennedy MA; Roberts R; Wilkinson TJ
Hum Psychopharmacol; 2002 Jun; 17(4):187-90. PubMed ID: 12404686
[TBL] [Abstract][Full Text] [Related]
20. Changes in the QTc interval after administration of flecainide acetate, with and without coadministered paroxetine, in relation to cytochrome P450 2D6 genotype: data from an open-label, two-period, single-sequence crossover study in healthy Korean male subjects.
Lim KS; Jang IJ; Kim BH; Kim J; Jeon JY; Tae YM; Yi S; Eum S; Cho JY; Shin SG; Yu KS
Clin Ther; 2010 Apr; 32(4):659-66. PubMed ID: 20435235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
